DARPA Just Revealed the 2 Best Quantum Computing Stocks to Buy Now

IonQ and IBM advanced to Stage C of DARPA’s Quantum Benchmarking Initiative, where participants may receive up to $300 million to validate plans for commercially viable fault-tolerant quantum computers by 2033. IonQ reports 99.99% two-qubit gate fidelity and an end-to-end real-time error-correction decoder; IBM targets its Starling fault-tolerant system for 2029. The article presents both as promising public quantum-computing investments, while noting IonQ currently leads in accuracy and IBM’s superconducting approach offers speed advantages.

Analysis

The investable signal is selection optionality, not near-term quantum revenue. Stage C raises the chance of federal support and gives technical claims a more rigorous validation path, but selection is not evidence of a funded award, commercial demand, or economic fault tolerance. The headline fidelity figures also may not be directly comparable across architectures or workloads; benchmark methodology and logical-qubit performance matter more than a single gate metric.

IONQ has the clearest potential upside sensitivity to successful milestones, but also the greatest risk that technical progress is capitalized before scalable economics are demonstrated. SkyWater integration could shorten prototype iteration and improve control over fabrication; the offset is execution risk and the possibility that internal quantum demand competes with other uses of capacity. IBM offers a less direct, more diversified way to own the theme: a quantum milestone is unlikely by itself to move consolidated earnings materially, while its roadmap could support strategic relevance if fault-tolerant systems become practical. Microsoft’s earlier Stage C position and Atom partnership provide ecosystem exposure, but do not establish material revenue contribution. QNT’s continued Stage B status is a relative catalyst disadvantage, not proof of technical inferiority; INFQ remains a competing neutral-atom exposure, with no advancement claim established here.

Near term, expect sentiment and milestone-driven volatility. Over 1–3 months, verify actual DARPA awards, funding terms, and independent benchmark detail. Over 6–18 months, the key tests are logical-qubit scaling, error-correction overhead, repeatable system performance, and customer use cases. The contrarian risk is treating government validation as a commercial winner-take-all signal: multiple architectures may advance, while economics and deployment timelines remain unresolved. Falsifiers include stalled error-correction demonstrations, roadmap delays, or evidence that performance gains fail to scale.

Key Decisions for Investors

• Do not chase IONQ solely on Stage C selection. Treat it as high-beta milestone exposure; add only after reviewing valuation and updated cash needs, and reassess if error-correction progress or system scaling slips.
• For lower single-company quantum risk, prefer IBM over a pure-play exposure as a conditional relative-value expression—not because quantum is an established earnings driver. Revisit if IBM delays its roadmap or quantum investment begins to pressure reported economics without measurable customer traction.
• Keep SKYT on an integration watchlist: verify acquisition close/integration milestones, capacity allocation, and whether quantum-related work translates into external foundry demand. The vertical-integration thesis weakens if prototype cadence or commercial execution does not improve.
• Track QNT and INFQ as competitive checks rather than assume Stage C winners have locked in leadership. Upgrade the view only on comparable, independently validated error-corrected performance or disclosed customer adoption; no near-term trade is warranted from selection status alone.